Back to discover
Drug

Chitosan

In clinical development
Emerging researchLate-stage developmentSteady momentum
8
Research papers
2
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Effect of Shockwaves on Fallopian Tubes Adhesion: a Randomized Controlled Trial

Clinical trial2025-02-28Primary completion · ClinicalTrials.gov

A review of current advancements for wound healing: Biomaterial applications and medical devices.

Research2022-05-17Journal of biomedical materials research. Part B, Applied biomaterials

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Chitosan
RxNorm CUI
59038

Clinical trials

11 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
11
registered trials across all phases
LATEST COMPLETION 2025
2
Active studies
2
Recruiting
7
Late-stage (III+)
6
Completed
3
Discontinued
PHASE DISTRIBUTIONn = 11
Early Phase 11Phase 12Phase 1 / 21Phase 32Phase 41Phase N / A4

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

8 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20182023
Most influential
Recent papers
Major research themes8
Chitosan3Bandages1Escherichia coli Infections1Fibroins1Gastrointestinal Microbiome1Inflammatory Bowel Diseases1Nanoparticles1Probiotics1
Journals, researchers & institutions
Top journals
  • International journal of molecular sciences3
  • Nature communications2
  • Journal of biomedical materials research. Part B, Applied biomaterials1
  • Journal of the American Chemical Society1
  • Molecules (Basel, Switzerland)1
Leading researchers
  • Li Q2
  • Liu J2
  • Liu Y2
  • Aachmann FL1
  • Ali MA1
  • Chen L1
  • Chen Q1
  • Deng X1
Leading institutions
free-text, unnormalised
  • Advanced Environmental Research Laboratories1
  • Centre for Bioengineering & Nanomedicine (Dunedin)1
  • Comenius University in Bratislava1
  • Engineering Research Center of Agricultural Microbiology Technology1
  • Frontier Institute of Science and Technology and State Key Laboratory for Mechanical Behavior of Materials1
  • Institute of Functional Nano & Soft Materials (FUNSOM)1

Related drugs

6 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 2 of the same disease areas as Chitosan in the shared literature.

2 shared diseases1 shared paper

Studied across 2 of the same disease areas as Chitosan in the shared literature.

2 shared diseases1 shared paper

Studied across the same disease area as Chitosan in the shared literature.

1 shared disease1 shared paper

Frequently co-studied with Chitosan in the research literature.

1 shared paper

Frequently co-studied with Chitosan in the research literature.

1 shared paper

Frequently co-studied with Chitosan in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials